Triple-nucleoside regimens versus efavirenz.
作者信息
De Luca Andrea, Di Giambenedetto Simona
出版信息
N Engl J Med. 2004 Aug 12;351(7):717-9; author reply 717-9. doi: 10.1056/NEJM200408123510720.
PMID:15306677
Abstract
摘要
相似文献
1
Triple-nucleoside regimens versus efavirenz.
N Engl J Med. 2004 Aug 12;351(7):717-9; author reply 717-9. doi: 10.1056/NEJM200408123510720.
2
Triple-nucleoside regimens versus efavirenz.
N Engl J Med. 2004 Aug 12;351(7):717-9; author reply 717-9.
3
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
N Engl J Med. 2004 Apr 29;350(18):1850-61. doi: 10.1056/NEJMoa031772.
4
Efavirenz in HIV infection.
N Engl J Med. 2000 Apr 27;342(17):1290-1. doi: 10.1056/NEJM200004273421713.
5
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
N Engl J Med. 1999 Dec 16;341(25):1865-73. doi: 10.1056/NEJM199912163412501.
6
7
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection.
N Engl J Med. 2001 Aug 9;345(6):398-407. doi: 10.1056/NEJM200108093450602.
8
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
AIDS Clin Care. 2006 Nov;18(11):99.
9
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
HIV Med. 2005 Nov;6(6):388-95. doi: 10.1111/j.1468-1293.2005.00315.x.
10
A new HAART on the horizon says the proof is in the potency.
AIDS Alert. 1999 Apr;14(4):37-9.
Zotero 插件